Brind.

A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.

Steady: 0 in the last 7 days Updated nov 11

The latest in this situation

  1. Valion briefed Pentagon officials on Entolimod, which is being studied with NIAID funding.

How it started

3 reports, 2 independent, last reported Aug 12. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Valion Bio's Entolimod, developed under FDA Animal Rule with NIAID funding, received Fast Track designation; facility in San Antonio, Texas.Sub-event
  2. NIAID funded a study at AFRRI to evaluate the therapeutic efficacy of a company's product.Sub-event
  3. Company partners with NIAID and AFRRI on protocol design reviewed by FDA.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story